Pharmacological body-wide and immunotropic effects of galavit in the treatment of patients with purulent-inflammatory diseases of various origins and allergization

Introduction: Patients with purulent-inflammatory diseases (PID), especially those with allergization, manifest chronicity, low treatment efficiency, and the risk of relapses; the above actualizes the search for innovative treatment technologies. The aim of the study: The aim of the study was to specify pharmacological (body-wide) and specific (immunotropic) effects of the immunomodulator galavit additionally prescribed in the context of basic treatment for patients with deep pyoderma, chronic pyelonephritis, adnexitis, purulent infection of soft tissues, complicated by atopic dermatitis. Materials and Methods: The study included 331 patients with PID and 30 healthy volunteers of the same age and gender who were examined prior and following the basic treatment of each nosoform. The diverse clinical and laboratory examination options were applied to investigate 17 clinical, 7 hematological, 16 immunological, 13 metabolic parameters that were grouped into clinical, hematological, immunological and metabolic syndromes, and divided into links – cellular, humoral, phagocytic, cytokine, metabolic and antioxidant. The results were statistically processed using variational parametric and nonparametric techniques; this allowed calculating the coefficient of diagnostic value, diagnostic formulas of disorders and targets of galavit under various conditions. Results and Discussion: Targeted pharmacological therapy with galavit reliably eliminates clinical, hemato-immuno-metabolic disorders in patients with PID, though dependently on the nosoform of the disease. Conclusion: It was demonstrated that the correction of clinical and laboratory disorders depend on PID pathogenesis and allergization; the laboratory mechanism of therapeutic effects was specified.